CA2886393C - Pentacyclic triterpenes for the treatment of obesity - Google Patents

Pentacyclic triterpenes for the treatment of obesity Download PDF

Info

Publication number
CA2886393C
CA2886393C CA2886393A CA2886393A CA2886393C CA 2886393 C CA2886393 C CA 2886393C CA 2886393 A CA2886393 A CA 2886393A CA 2886393 A CA2886393 A CA 2886393A CA 2886393 C CA2886393 C CA 2886393C
Authority
CA
Canada
Prior art keywords
celastrol
obese
mice
alkyl
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2886393A
Other languages
English (en)
French (fr)
Other versions
CA2886393A1 (en
Inventor
Umut Ozcan
Joseph MAJZOUB
Ralph Mazitschek
Isin CAKIR
Serkan CABI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Boston Childrens Hospital
Original Assignee
General Hospital Corp
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2886393(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp, Boston Childrens Hospital filed Critical General Hospital Corp
Priority to CA3030272A priority Critical patent/CA3030272C/en
Publication of CA2886393A1 publication Critical patent/CA2886393A1/en
Application granted granted Critical
Publication of CA2886393C publication Critical patent/CA2886393C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2886393A 2012-09-27 2013-09-26 Pentacyclic triterpenes for the treatment of obesity Active CA2886393C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3030272A CA3030272C (en) 2012-09-27 2013-09-26 Pentacyclic triterpenes for the treatment of obesity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706153P 2012-09-27 2012-09-27
US61/706,153 2012-09-27
PCT/US2013/061911 WO2014052583A1 (en) 2012-09-27 2013-09-26 Compounds for the treatment of obesity and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3030272A Division CA3030272C (en) 2012-09-27 2013-09-26 Pentacyclic triterpenes for the treatment of obesity

Publications (2)

Publication Number Publication Date
CA2886393A1 CA2886393A1 (en) 2014-04-03
CA2886393C true CA2886393C (en) 2019-02-26

Family

ID=49304418

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3030272A Active CA3030272C (en) 2012-09-27 2013-09-26 Pentacyclic triterpenes for the treatment of obesity
CA2886393A Active CA2886393C (en) 2012-09-27 2013-09-26 Pentacyclic triterpenes for the treatment of obesity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA3030272A Active CA3030272C (en) 2012-09-27 2013-09-26 Pentacyclic triterpenes for the treatment of obesity

Country Status (21)

Country Link
US (6) US9968575B2 (enExample)
EP (3) EP2900230B1 (enExample)
JP (2) JP6480864B2 (enExample)
CN (3) CN111529535A (enExample)
AU (3) AU2013323528B2 (enExample)
BR (1) BR112015006848A2 (enExample)
CA (2) CA3030272C (enExample)
CY (1) CY1121166T1 (enExample)
DK (1) DK2900230T3 (enExample)
ES (1) ES2696626T3 (enExample)
HR (1) HRP20181879T1 (enExample)
HU (1) HUE040496T2 (enExample)
LT (1) LT2900230T (enExample)
PL (1) PL2900230T3 (enExample)
PT (1) PT2900230T (enExample)
RS (1) RS58010B1 (enExample)
RU (2) RU2768868C2 (enExample)
SI (1) SI2900230T1 (enExample)
SM (1) SMT201800604T1 (enExample)
TR (1) TR201815668T4 (enExample)
WO (1) WO2014052583A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968575B2 (en) 2012-09-27 2018-05-15 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
AU2015235979B2 (en) * 2014-03-26 2019-05-02 The Children’s Medical Center Corporation Celastrol and derivatives for the treatment of obesity
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105985401B (zh) * 2015-02-16 2020-10-09 上海华拓医药科技发展有限公司 一种雷公藤红素衍生物、其制备方法及用途
CN108601751A (zh) 2015-10-23 2018-09-28 Erx制药股份有限公司 雷公藤红素的类似物
CN106905404B (zh) * 2017-01-13 2019-08-27 广东工业大学 熊果酸衍生物及其制备方法和应用
CN116509842B (zh) * 2021-09-09 2024-09-20 厦门君德医药科技有限公司 药物组合物及其制备方法和应用
KR102470686B1 (ko) * 2022-06-07 2022-11-23 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
EP0832220A1 (en) 1995-06-07 1998-04-01 Amgen Inc. Ob protein compositions and method
PL324284A1 (en) 1995-06-30 1998-05-11 Lilly Co Eli Methods of treating diabetes
EP0865294B1 (en) 1995-08-17 2004-02-18 Amgen Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
NZ527007A (en) 1995-11-22 2005-01-28 Amgen Inc Methods of increasing lean tissue mass using OB protein compositions
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
WO1998008512A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
PL332458A1 (en) 1996-09-20 1999-09-13 Hoechst Ag Application of leptin antagonists in treating insulin resistance in cases of diabeted of type ii
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
ATE351910T1 (de) 1996-12-20 2007-02-15 Amgen Inc Ob-fusionsprotein enthaltende zusammensetzungen und verfahren
ES2183351T3 (es) 1997-04-17 2003-03-16 Amgen Inc Composicones que comprenden conjugados de proteina ob humana activa estable con una cadena fc de inmunoglobulinas y metodos.
IL133136A0 (en) 1997-06-06 2001-03-19 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
WO2000009165A1 (en) 1998-08-10 2000-02-24 Amgen Inc. Dextran-leptin conjugates, pharmaceutical compositions and related methods
CA2344623A1 (en) 1998-10-02 2000-04-13 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CA2359840C (en) 1999-02-12 2012-10-23 Amgen Inc. Glycosylated leptin compositions and related methods
EP1444516B1 (en) 2001-10-22 2010-07-21 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
JP2006508182A (ja) * 2002-10-21 2006-03-09 メタプロテオミクス， エルエルシー 炎症応答と関連した病理学的状態を処置または抑制する組成物。
AU2003290563A1 (en) 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
EP1715539B1 (en) 2004-01-16 2012-11-07 Mitsubishi Materials Corporation Separator for fuel cell, method of producing separator, and solid oxide fuel cell
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
ES2575515T3 (es) 2005-09-30 2016-06-29 Morinaga Milk Industry Co., Ltd. Agente para mejorar la resistencia a la insulina
AU2006308655B2 (en) 2005-11-01 2010-09-23 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
WO2007111994A2 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
US20110263693A1 (en) * 2006-03-31 2011-10-27 Dana-Farber Cancer Institute, Inc. Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
TW200824678A (en) 2006-08-11 2008-06-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
WO2008020622A1 (en) * 2006-08-17 2008-02-21 Kyorin Pharmaceutical Co., Ltd. NOVEL THIENO[2,3-d]PYRIMIDINE COMPOUND
US20100240581A1 (en) * 2006-11-13 2010-09-23 The Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
CN101279995A (zh) * 2007-04-03 2008-10-08 烟台靶点药物研究有限公司 一种雷公藤红素盐及其制备方法与用途
US7776894B2 (en) 2007-08-17 2010-08-17 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
JP2011503180A (ja) * 2007-11-14 2011-01-27 アミリン・ファーマシューティカルズ，インコーポレイテッド 肥満ならびに肥満関連の疾患および障害の処置方法
CN101434635B (zh) 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
JP2011511007A (ja) * 2008-02-01 2011-04-07 ザ スクリプス リサーチ インスティチュート タンパク質ホメオスタシスの機能不全を特徴とする状態を治療するための方法
CN101352444A (zh) * 2008-09-11 2009-01-28 中国科学院广州生物医药与健康研究院 雷公藤红素在制药中的新应用
JP5780549B2 (ja) * 2009-04-17 2015-09-16 国立大学法人広島大学 レプチン抵抗性を改善および／または予防するための薬学的組成物、並びにその使用
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
ES2768204T3 (es) 2010-04-12 2020-06-22 Reata Pharmaceuticals Inc Metil bardoxolona para el tratamiento de la obesidad
CN101805390B (zh) 2010-04-13 2012-07-18 暨南大学 一种雷公藤红素衍生物及其用途
CN102309494A (zh) * 2010-07-01 2012-01-11 嘉兴学院 扁蒴藤素作为炎性细胞因子抑制剂的医药用途
US8691977B2 (en) 2010-08-23 2014-04-08 Neupharma, Inc. Certain chemical entities, compositions, and methods
JP5816626B2 (ja) * 2010-09-17 2015-11-18 武田薬品工業株式会社 糖尿病治療剤
KR101180387B1 (ko) 2011-11-21 2012-09-10 동국대학교 산학협력단 엣지 추출을 위한 이미지 센서 및 이를 이용한 엣지 이미지 생성 방법.
CN104812898B (zh) 2012-05-25 2018-01-30 博格有限责任公司 通过调节热休克蛋白质(HSP)90‑β治疗代谢综合征的方法
US9968575B2 (en) * 2012-09-27 2018-05-15 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
CN103524592B (zh) 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure

Also Published As

Publication number Publication date
CN104822374A (zh) 2015-08-05
PT2900230T (pt) 2018-11-26
AU2016247206B2 (en) 2018-08-02
AU2013323528A1 (en) 2015-04-09
US20150250753A1 (en) 2015-09-10
DK2900230T3 (en) 2018-11-12
US11045439B2 (en) 2021-06-29
JP2015531376A (ja) 2015-11-02
CY1121166T1 (el) 2020-05-29
JP6743211B2 (ja) 2020-08-19
RU2768868C2 (ru) 2022-03-25
US9925161B2 (en) 2018-03-27
JP6480864B2 (ja) 2019-03-13
CA3030272C (en) 2021-09-28
EP3434268A1 (en) 2019-01-30
AU2016247206A1 (en) 2016-11-10
CA2886393A1 (en) 2014-04-03
EP3434268B1 (en) 2022-04-20
CN111529535A (zh) 2020-08-14
SI2900230T1 (sl) 2019-01-31
ES2696626T3 (es) 2019-01-17
US20170304245A1 (en) 2017-10-26
AU2018256619B2 (en) 2020-07-23
JP2019070052A (ja) 2019-05-09
TR201815668T4 (tr) 2018-11-21
RU2015115696A (ru) 2016-11-20
CN111529534A (zh) 2020-08-14
PL2900230T3 (pl) 2019-02-28
BR112015006848A2 (pt) 2018-05-22
US20180185314A1 (en) 2018-07-05
US20210275482A1 (en) 2021-09-09
RU2650646C2 (ru) 2018-04-16
AU2018256619A1 (en) 2018-11-22
RU2018112067A (ru) 2019-03-07
US10653654B2 (en) 2020-05-19
AU2013323528B2 (en) 2016-11-10
EP2900230A1 (en) 2015-08-05
US12064408B2 (en) 2024-08-20
LT2900230T (lt) 2019-01-10
EP2900230B1 (en) 2018-08-15
EP4082541A1 (en) 2022-11-02
RS58010B1 (sr) 2019-02-28
HK1213190A1 (en) 2016-06-30
US20210008019A1 (en) 2021-01-14
US9968575B2 (en) 2018-05-15
HUE040496T2 (hu) 2019-03-28
SMT201800604T1 (it) 2019-01-11
HRP20181879T1 (hr) 2019-02-08
CA3030272A1 (en) 2014-04-03
WO2014052583A1 (en) 2014-04-03
RU2018112067A3 (enExample) 2021-06-24
US20250161252A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
US20250161252A1 (en) Compounds for the treatment of obesity and methods of use thereof
CA2944030C (en) Celastrol and derivatives for the treatment of obesity
AU2018200517B2 (en) Compounds for the treatment of obesity and methods of use thereof
WO2015153933A1 (en) Hsp90 inhibitors for the treatment of obesity and methods of use thereof
HK40083451A (en) Compounds for the treatment of obesity and methods of use thereof
HK1233923A1 (en) Celastrol derivatives for the treatment of obesity
HK1233923B (en) Celastrol derivatives for the treatment of obesity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150326